RAD51 and neoplasm: More recently, 3E10 was found to bind RAD51 and to be synthetically lethal in BRCA2- and PTEN-deficient cells [33], and new pre-clinical studies have also demonstrated the ability of 3E10 to deliver nucleic acids into tumor cells (with functional release) following systemic administration [23].